Lys Therapeutics develops a first-in-class monoclonal antibody counteracting the neuroinflammatory and neurodegenerative processes implicated in the pathophysiology of neurological diseases by restoring the physiological function of the blood-brain barrier.

Pre-Seed, Seed & Series A investments

Euronext listed company, implementing strategic business evolutions

GAOMA Therapeutics develops bioactive lipids as first-in-class drug-candidates, notably for neurological and inflammatory disorders.- run company inception, handled general management and established development strategy- handled funding processes, secured >€4m as seed financing (equity, non-dilutive)- structured team and governance- supervised R&D operations, lead drug-candidate targeting epilepsy and cognitive disorders- implemented strategic partnerships with private and public organizations

NETRIS Pharma is a clinical-stage immuno oncology company, developing first-in-class monoclonal antibodies against dependance receptors.- handled operational, financial, administrative, IP and HR management of the company- led operations for one clinical-stage program and several preclinical-stage programs- established development plans and related budgets, provided strategic perspective- contributed to business development with Pharmas and VCs- got involved in negotiations for fund raising, M&A and out-licensing deals- coordinated and supported due diligence processes, set up the data room- delivered support in interactions with regulatory agencies and firms (CTA, pre-IND)- supported the CEO in strategic initiatives and corporate governance matters- monitored recruitment of project teams, risk assessment, identification of strategic, financial and logistic solutions

- managed operations in an international environment for five R&D programs- led and executed the transition from preclinical to clinical stage with a successful CTA (First-in-Class, First-in-Human)- implemented and handled budgeting system, accounting follow-up, financial flows monitoring, reporting to shareholders- supported IP management (about ten patents/licenses) with partner consultancy and several academic institutions- contributed to grants applications and administrated grants programs (French and European calls) for a total amount over 6M€

- reviewed and analyzed integrated health solutions on the French market- developed business modeling around a Combined Offer concept in oncology, fertility and neurology- got involved in the establishment of economic valuation strategy to public and private payers- modeled business plan economics for three new projects

- administration of serious adverse events (SAE) reported during clinical trials and follow-up of SAE- implementation of a new pharmacovigilance database, writing of 10 procedures- management of the new database validation: this work led to a thesis

- review on amorphous forms stabilisation- experiments on solubility of new molecules intended for preclinical trials